Stock market announcements Archive - Page 12 of 27

Lifecare – Sanofi Product Development Agreement Update

September 19, 2023
Reference is made to previous investor communication, i.e. September 23, 2021and later. Lifecare is engaged with Sanofi in a Product Development Agreementaimed at advancing the miniaturization of Lifecare's sensor technology forintegration into Lifecare's Sencell Continuous Glucose Monitoring system.Under the terms of the agreement, Sanofi has committed to provide fundingcontributions, supporting the further development of Lifecare's […]
Read more

LIFE: Towards market readiness

August 23, 2023
Lifecare has shown major progress in our plan to bring the smallest ContinuousGlucose Monitor (CGM) system to the market. Testing in live tissue,implementation of Quality Management System and set up of manufacturingcapabilities form the three main pillars in our market-oriented development. - The results from studies concluded in 1H 2023 and the status of the […]
Read more

LIFE: Lifecare 2023 semi-annual report and webcast

August 22, 2023
Lifecare AS will present 1H 2023 financial and operational status in a webcastWednesday 23 August. The webcast will be for all shareholders and interestedparties at 09:30 - 10:15 CET.The Swedish research powered investment bank Redeye AB will host the webcast.Lifecare's CEO Joacim Holter presents the company's Semi Annual report followedby a Q&A with Redeye's analyst […]
Read more

Lifecare sensor longevity experiment concluded: 6 months operational lifetime

July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more

LIFE: CLINICAL STUDY RESULTS PRESENTED AT AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS 2023

June 27, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 was presented at theAmerican Diabetes Association (ADA) Scientific Sessions 2023. Lifecare's posterpresentation reveals the study background, methods, and results. The resultsinclude an impressive mean average of absolute error (MARD) of 9,6%, positioningLifecares's Sencell technology with an accuracy that is acceptable fortherapeutic (medical) decisions such as insulin dose adjustments. […]
Read more

LIFE: LIFECARE STUDY CONFIRM CLINICAL ACCURACY IN LINE WITH GOLD STANDARD

June 20, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 confirm that theCompany's Continuous Glucose Monitoring (CGM) system (Sencell) has a solidclinical accuracy: the mean average of absolute error (MARD) between Sencell andmatched relative reference values was 9,6%. In context, regulatory authorities expect a MARD below 10% to acknowledge CGMfor therapeutic (medical) decisions such as insulin dose adjustments. […]
Read more

LIFE: Lifecare launches spin-off company with successful veterinarian

May 30, 2023
Lifecare, which is developing a long-lasting glucose sensor with the size of agrain of rice, is launching a new company called Lifecare Veterinary. Now man'sbest friend will also benefit from the same innovation. - Our main focus will still be the development of the sensor for people withdiabetes, increasing their quality of life. This is […]
Read more

Lifecare investor presentation – Redeye Diabetes Event

May 24, 2023
Lifecare will attend the Redeye Diabetes Event 2023 today and presents thecompany's technology status and development at 11:05 AM CEST. The presentations are live broadcasted athttps://www.redeye.se/events/870294/redeye-theme-diabetes and the presentationslides is enclosed to this notification. ABOUT LIFECARELifecare AS is a clinical stage medical sensor company developing technology forsensing and monitoring of various body analytes. Lifecare's main […]
Read more

LIFE: Lifecare presentation at Redeye Diabetes Event, 24 May 2023

May 22, 2023
Lifecare CEO Joacim Holter will presents the company's technology status anddevelopment at Redeye Diabetes Event 2023 on May 24 at 11:05 AM CEST. The presentations are live broadcasted athttps://www.redeye.se/events/870294/redeye-theme-diabetesABOUT LIFECARELifecare AS is a clinical stage medical sensor company developing technology forsensing and monitoring of various body analytes. Lifecare's main focus is tobring the next generation […]
Read more

LIFE: Lifecare newsletter

May 12, 2023
Bergen, Norway 12 May 2023 Lifecare's latest updates include information of the recently finalized clinicalstudy and the presentation of study results on the upcoming American DiabetesAssociation Congress in San Diego, the company's Q1 2023 report, ISO 9001certification of Lifecare Laboratory and the progress for our plannedmanufacturing site in Mainz, Germany. Read more in Lifecare's newsletter […]
Read more